Cardiovascular Systems (Cardiovascular Systems) Risk Assessment

View and export this data going back to 2006. Start your Free Trial

What is Cardiovascular Systems Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Cardiovascular Systems is: No Data: Cannot be evaluated.

Competitive Comparison of Cardiovascular Systems's Risk Assessment

For the Medical Devices subindustry, Cardiovascular Systems's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiovascular Systems's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cardiovascular Systems's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Cardiovascular Systems's Risk Assessment falls into.

Cardiovascular Systems (NAS:CSII) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Cardiovascular Systems Risk Assessment Related Terms

Thank you for viewing the detailed overview of Cardiovascular Systems's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiovascular Systems (Cardiovascular Systems) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cardiovascular Systems Inc (NAS:CSII) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

1225 Old Highway 8 Northwest, Saint Paul, MN, USA, 55112-6416

Website

https://www.csi360.com

Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.

Executives

Jeffrey S. Points	officer: Chief Financial Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Scott R Ward	director	RAYMOND HOLDINGS, LLC, 6410 BALLANTINE CT., INVER GROVE HEIGHTS MN 55077
Erik Paulsen	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Rhonda J. Robb	officer: Chief Operating Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Martha Goldberg Aronson	director	40 WEST HIGHLAND PARK DRIVE NE, HUTCHINSON MN 55350
Sachin H. Jain	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Alexander Rosenstein	officer: General Counsel & Corp. Secy	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Sandra Sedo	officer: Chief Compliance Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Kelvin K. Womack	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen J. Rempe	officer: Chief Human Resources Officer	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
John M. Hastings	officer: VP Manufacturing & Operations	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Stephen Stenbeck	director	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Ryan Egeland	officer: VP of Medical Affairs	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
David Whitescarver	officer: VP of Corp. Dev. & IP	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Laura Gillund	officer: Chief Talent Officer